Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Quality Of Life, Pharmacoeconomic Guidance Development On Hold

Executive Summary

FDA development of guidances for including quality of life claims in drug labeling and promotions and for formulary-directed pharmacoeconomic information is on hold until more information is collected.
Advertisement

Related Content

P&T Committees Would Be Powerful Force Under Medicare Rx
P&T Committees Would Be Powerful Force Under Medicare Rx
FDA Quality Of Life Guidance Receives Renewed Interest After Industry Input
FDA Quality Of Life Guidance Receives Renewed Interest After Industry Input
FDA Ad Division Will Increase Focus On Outcomes Claims After Reorganization
Bristol Ifex Website Promotes Off-Label Indications, FDA Ad Division Says
Formulary-Tailored Pharmacoeconomic Models Being Used By Rx Sales Reps
FDA Accepts Drug Quality Of Life Claims From Secondary Endpoints - Bristol
FDA Gene Therapy Survey Seeks Info On Quality Controls & Monitoring
FDA Gene Therapy Survey Seeks Info On Quality Controls & Monitoring
Advertisement
UsernamePublicRestriction

Register

PS037511

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel